title: From the Food and Drug Administration.
authors: Office of the Commissioner of Food and Drugs, Food and Drug Administration, Rockville, MD 20857, USA.
authors: B A
authors: BA
authors: Schwetz
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077868:Atrasentan; D001549:Benzamides; D017277:Drug Approval; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009965:Orphan Drug Production; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D011759:Pyrrolidines; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D011759:Pyrrolidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000077868:Atrasentan